S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:NPCE

NeuroPace (NPCE) Stock Forecast, Price & News

$7.89
+0.09 (+1.15%)
(As of 09/22/2023 ET)
Compare
Today's Range
$7.71
$8.00
50-Day Range
$4.00
$9.39
52-Week Range
$1.22
$9.50
Volume
29,973 shs
Average Volume
112,816 shs
Market Capitalization
$204.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

NeuroPace MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1.4% Upside
$8.00 Price Target
Short Interest
Healthy
4.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.53) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

803rd out of 963 stocks

Surgical & Medical Instruments Industry

84th out of 97 stocks


NPCE stock logo

About NeuroPace (NASDAQ:NPCE) Stock

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Price History

NPCE Stock News Headlines

Morgan Stanley Upgrades NeuroPace (NPCE)
WARNING: Seven millionaires to trigger sudden market panic?
The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
NeuroPace, Inc.: NeuroPace Announces CEO Transition
NeuroPace Announces CEO Transition
Recap: NeuroPace Q1 Earnings
NeuroPace Stock (NASDAQ:NPCE), Dividends
See More Headlines
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

NPCE Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-47,080,000.00
Pretax Margin
-77.25%

Debt

Sales & Book Value

Annual Sales
$45.52 million
Book Value
$1.40 per share

Miscellaneous

Free Float
18,749,000
Market Cap
$204.04 million
Optionable
Not Optionable
Beta
1.97
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Ms. Irina RidleyMs. Irina Ridley (Age 37)
    Chief Legal Officer & Corp. Sec.
    Comp: $499.31k
  • Dr. Martha J. Morrell (Age 66)
    Chief Medical Officer
    Comp: $555.87k
  • Mr. Joel D. Becker (Age 55)
    CEO & Director
  • Ms. Rebecca L. Kuhn (Age 62)
    CFO, VP of Fin. & Admin. and Assistant Sec.
  • Ms. Kelley Nicholas
    VP of Sales
  • Ms. Irene Thomas (Age 54)
    VP of HR
  • Mr. Andre G. Marquette
    Chief Commercial Officer













NPCE Stock - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings
or view top-rated stocks.

What is NeuroPace's stock price forecast for 2023?

2 equities research analysts have issued 1 year price objectives for NeuroPace's stock. Their NPCE share price forecasts range from $6.00 to $10.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for NPCE
or view top-rated stocks among Wall Street analysts.

How have NPCE shares performed in 2023?

NeuroPace's stock was trading at $1.49 on January 1st, 2023. Since then, NPCE stock has increased by 429.5% and is now trading at $7.89.
View the best growth stocks for 2023 here
.

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NPCE earnings forecast
.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.11. The business earned $16.51 million during the quarter, compared to analysts' expectations of $12.74 million. NeuroPace had a negative net margin of 77.25% and a negative trailing twelve-month return on equity of 133.74%.

What guidance has NeuroPace issued on next quarter's earnings?

NeuroPace updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $59.00 million-$61.00 million, compared to the consensus revenue estimate of $52.85 million.

When did NeuroPace IPO?

(NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

What is NeuroPace's stock symbol?

NeuroPace trades on the NASDAQ under the ticker symbol "NPCE."

Who are NeuroPace's major shareholders?

NeuroPace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kent Lake Capital LLC (0.58%), BlackRock Inc. (0.14%) and Renaissance Technologies LLC (0.07%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroPace's stock price today?

One share of NPCE stock can currently be purchased for approximately $7.89.

How much money does NeuroPace make?

NeuroPace (NASDAQ:NPCE) has a market capitalization of $204.04 million and generates $45.52 million in revenue each year. The company earns $-47,080,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does NeuroPace have?

The company employs 169 workers across the globe.

How can I contact NeuroPace?

The official website for the company is www.neuropace.com. The company can be reached via phone at 650-237-2700 or via email at investors@neuropace.com.

This page (NASDAQ:NPCE) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -